Septerna, Inc.
A clinical-stage biotechnology company crafting oral small-molecule medicines aimed at G protein-coupled receptors (GPCRs), cell-surface proteins tied to many diseases that have historically been hard to drug. Its scientists use a 'Native Complex Platform' to isolate and study these receptors in a form that mimics the body's cell membranes. Founded in 2019 by Nobel laureate Robert Lefkowitz and colleagues, the company's name blends 'sept,' for the receptors' seven membrane-spanning domains, with 'terna,' from the model he developed for how they work.
Bought 1.71M
Bought 4.17M
Granted 55.0K · Bought 17.0K
Granted 8.0K · Sold 8.0K
Granted 23.0K
Bought 100.0K
Granted 15.0K · Sold 18.5K
Bought 40.0K
Granted 96.6K · Sold 96.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| TRV GP V, LLC +5 co-filers10% owner · 7 transactions | — | 22.30Mas of Feb 2025 | — | 1.71M | — |
| Kolchinsky Peter +4 co-filersDirector, 10% owner, Director · 4 transactions | — | 1.47Mas of Oct 2024 | — | 4.17M | — |
| Finer JeffreyCEO and President, Director · 5 transactions | — | 826.9Kas of Apr 2025 | 55.0K | 17.0K | — |
| Bhatt ElizabethPresident and COO · 7 transactions | — | 174.5K | 8.0K | — | 8.0K |
| Klein UweSVP, Biological Sciences · 3 transactions | — | 119.9Kas of Aug 2025 | 23.0K | — | — |
| Ezekowitz AlanDirector · 4 transactions | — | 117.4Kas of Mar 2025 | — | 100.0K | — |
| Long Daniel D.SVP, Drug Discovery · 5 transactions | — | 111.4K | 15.0K | — | 18.5K |
| Labrucherie Gil MChief Financial Officer · 5 transactions | — | 40.0Kas of Feb 2025 | — | 40.0K | — |
| Shaikhly SamiraChief People Officer · 17 transactions | — | 793 | 96.6K | — | 96.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +5.91M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.